Abstract: A process for preparing (R)-3-amino-5-methoxychroman is provided. The process comprises the steps of (i) dissolving racemic 3-amino-5-methoxychroman and L(+)tartaric acid in water to form the tartrate salt; (ii) heating the solution until a clear solution is obtained; and (iii) crystallizing the tartrate salt by allowing the solution to cool to room temperature.

Abstract: A microbubble preparation formed of a plurality of microbubbles comprising a first gas and a second gas surrounded by a membrane such as a surfactant, wherein the first gas and the second gas are present in a molar ratio of from about 1:100 to about 1000:1, and wherein the first gas has a vapor pressure of at least about (760-x) mm Hg at 37.degree. C., where x is the vapor pressure of the second gas at 37.degree. C., and wherein the vapor pressure of each of the first and second gases is greater than about 75 mm Hg at 37.degree. C.; also disclosed are methods for preparing microbubble compositions, including compositions that rapidly shrink from a first average diameter to a second average diameter less than about 75% of the first average diameter and are stabilized at the second average diameter; kits for preparing microbubbles; and methods for using such microbubbles as ultrasound contrast agents.

Abstract: Liposomes suitable as ultrasound contrast agents which contain media of various types including gases, gaseous precursors activated by pH, temperature or pressure, as well as other solid or liquid contrast enhancing agents, are described. Methods of using the same as ultrasound contrast agents are also disclosed. The present invention also comprises novel methods for synthesizing liposomes having encapsulated therein gases.

Abstract: This invention relates to compounds which inhibit lipoxygenase in the metabolism of arachidonic acid and thus inhibits formation of leukotrienes which are implicated in inflammatory processes and bronchoconstriction and inhibits the oxidation of LDL which is implicated in formation of atherosclerotic plaque.The compounds useful in this invention are represented by the formula: ##STR1## wherein: R.sup.2 is hydrogen, halogen or C.sub.1 -C.sub.6 alkyl; Y of O or S;R.sup.5 is hydrogen or methylR.sup.6 is --NH.sub.2, --CH.sub.3 or --OCH.sub.3 ;and R.sup.1 is ##STR2## wherein R.sup.7, R.sup.8 and R.sup.10 are independently halogen, trifluoromethyl, alkyl, alkoxy, methanesulfonyl or trifluoromethanesulfonyl; R.sup.9 is hydrogen or methyl; and Z is O or S,or a pharmaceutically acceptable salt thereof.

Abstract: There is provided an insecticidal composition comprising, in admixture with an agriculturally acceptable carrier, an insecticidally effective amount of a tetrahydroquinazoline compound of the formula ##STR1## wherein R, R.sup.1, R.sup.2, R.sup.3, R.sup.5, R.sup.6, R.sup.7, R.sup.8, and R.sup.9 are as defined herein, and methods of using the same. Certain novel substituted-phenyl tetrahydroquinazoline compounds per se are also identified.

Abstract: Novel herbicidal fluorobenzothiazolyloxyacetamides of the formula ##STR1## in which R.sup.1 represents hydrogen or an optionally substituted radical from the group consisting of alkyl, alkenyl, alkinyl and aralkyl,R.sup.2 represents an optionally substituted radical from the group consisting of alkyl, alkenyl, alkinyl, cycloalkyl, cycloalkenyl, aralkyl, aryl, alkoxy, alkenyloxy or alkinyloxy, orR.sup.1 and R.sup.2, together with the nitrogen atom to which they are bonded, form an optionally substituted, saturated or unsaturated nitrogen heterocycle which can contain further heteroatoms and to which a benzo group can be fused.

Abstract: While performing cardiopulmonary bypass, the aorta is cross-clamped and the beating heart is stopped by introducing of an ATP-dependent potassium channel opening agent. The infusion into the coronary circulation shortens the cardiac action potential thereby arresting the heart muscle at a hyperpolarized membrane potential. This maintains the heart in a state of minimal metabolic requirement, thereby preserving transmembrane ionic gradients, intercellular energy stores and cellular integrity. Cardiac arrest is reversed simply by flushing the heart by the coronary circulation upon removal of the aortic cross-clamp. This use is also germane to organ preservation during transport for transplantation. For example, the donor heart is arrested using an ATP-dependent potassium channel opening agent, it is then removed and transported to the recipient and transplanted. Cardiac arrest is reversed by reperfusing the orthotropic graft.

Abstract: Modulators of neurotransmitter release including substituted guanidines, N"-aminoguanidines, and N,N'N",N"'-tetrasubstituted hydrazinedicarboximidamides, and pharmaceutical compositions thereof are disclosed. Also disclosed are methods involving the use of such neurotransmitter release modulators for the treatment or prevention of pathophysiologic conditions characterized by the release of excessive or inappropriate levels of neurotransmitters. Also disclosed are screening assays for compounds which selectively inhibit glutamate release. Also disclosed are methods of blocking voltage sensitive sodium and calcium channels in mammalian nerve cells.

Abstract: The invention relates to surfactant containing, liquid compositions based on the magnesium salt of primary alcohol sulphates and provides and aqueous, liquid, cleaning composition having a pH from 6-8, comprising:a) 2-40% wt surfactant, said surfactant comprising primary alcohol sulphate (i) and nonionic surfactants (ii) wherein at least 50% wt of the surfactant present is primary alcohol sulphate, said surfactant comprising less than 1% on surfactant of nitrogen-containing surfactant speciesb) magnesium, at a Molar ratio of at least 0.3 moles Mg per mole primary alcohol sulphate.

Abstract: Novel herbicidal fluorobenzothiazolyloxyacetamides of the formula ##STR1## in which R.sup.1 represents hydrogen or an optionally substituted radical from the group consisting of alkyl, alkenyl, alkinyl and aralkyl,R.sup.2 represents an optionally substituted radical from the group consisting of alkyl, alkenyl, alkinyl, cycloalkyl, cycloalkenyl, aralkyl, aryl, alkoxy, alkenyloxy or alkinyloxy, orR.sup.1 and R.sup.2, together with the nitrogen atom to which they are bonded, form an optionally substituted, saturated or unsaturated nitrogen heterocycle which can contain further heteroatoms and to which a benzo group can be fused.

Abstract: Liposomes suitable as ultrasound contrast agents which contain media of various types including gases, gaseous precursors activated by pH, temperature or pressure, as well as other solid or liquid contrast enhancing agents, are described. Methods of using the same as ultrasound contrast agents are also disclosed. The present invention also comprises novel methods for synthesizing liposomes having encapsulated therein gases.

Abstract: A process for producing sulfolane compounds is provided which comprises: (1) contacting a conjugated diene with sulfur dioxide under conditions sufficient to synthesize a sulfolene compound whereby a mixture of the sulfolene compound and impurities comprising unreacted sulfur dioxide is produced; (2) transferring the mixture to an impurities removal vessel containing a freezing point depressant which comprises an aromatic compound; (3) removing the impurities; (4) transferring the impurities-reduced sulfolene compound to a hydrogenation reactor; (5) contacting the impurities-reduced sulfolene compound with hydrogen, in the presence of a hydrogenation catalyst, under conditions sufficient to produce a sulfolane compound; and (6) optionally recovering the sulfolane compound.

Abstract: Novel compounds of the formula ##STR1## where X is S, O; R.sub.1 -R.sub.5 are hydrogen or lower alkyl; R.sub.6 is lower alkyl, lower alkenyl, lower cycloalkyl having 1 to 6 carbons, or halogen; A is lower branched chain alkyl having 2 to 6 carbons, cycloalkyl having 3 to 6 carbons, alkenyl having 2 to 6 carbons and 1 or 2 double bonds, alkynyl having 2 to 6 carbons and 1 or 2 triple bonds, (CH.sub.2).sub.n where n is 0-5; and B is hydrogen, COOH or a pharmaceutically acceptable salt thereof, COOR.sub.8, COONR.sub.9 R.sub.10, --CH.sub.2 OH, CH.sub.2 OR.sub.11, CH.sub.2 OCOR.sub.11, CHO, CH(OR.sub.12).sub.2, CHOR.sub.13 O, --COR", CR"(OR.sub.12).sub.2, or CR"OR.sub.13 O, where R" is an alkyl, cycloalkyl or alkenyl group containing 1 to 5 carbons, R.sub.8 is an alkyl group of 1 to 10 carbons, or a cycloalkyl group of 5 to 10 carbons, or R.sub.8 is phenyl or lower alkylphenyl, R.sub.9 and R.sub.

Abstract: Liposomes suitable as ultrasound contrast agents which contain media of various types including gases, gaseous precursors activated by pH, temperature or pressure, as well as other solid or liquid contrast enhancing agents, are described. Methods of using the same as ultrasound contrast agents are also disclosed. The present invention also comprises novel methods for synthesizing liposomes having encapsulated therein gases.

Abstract: The present invention involves monomeric compounds having the structure: ##STR1## Substituents W and Z are independently --CN, --NO.sub.2, --aryl, --aryl--V, --COX, SO.sub.2 R, --H, or --alkyl. Substituent X is --OR, or --NR,R where R and R.sup.1 are independently --alkyl or --H. Substituent V is --halide, --NO.sub.2, --CN, --SO.sub.2 R, or --COX. At least one of W and Z is --NO.sub.2, --SO.sub.2 R, --CN, --COX or --aryl--V. In one preferred embodiment substituents W and Z are both --CN. In another preferred embodiment, substituent X is --NO.sub.2 or --CN and substituent Z is --C.sub.6 H.sub.4 NO.sub.2. These monomers are polymerized to form low bandgap polymers.

Abstract: In a process for preparing alkylene sulfides through the intramolecular dehydration reaction of mercaptoalkanols in a gaseous phase, catalysts are used, which are represented by the formula: M.sub.a X.sub.b Y.sub.c O.sub.d, where M represents at least one element selected from the group of alkali metals, alkaline earth metals and thallium; X represents at least one element selected from the group of Al, B, Si and P; Y represents at least one element selected from the group consisting of lanthanides, IIIA group, IVA group, VA group, IIIB group, IVB group, VB group and VIB group, excluding an element contained in M or X; O represents oxygen; and a and b are numerical values not equal to 0; b=0.2-100 and c=0-50 when a=1; and d is a numerical value determined according to a, b and c.

Abstract: A novel heterocyclic amine derivative of the general formula: ##STR1## wherein a ring A and a ring B stand independently for an optionally substituted benzene ring, Z.sup.o stands for O or S or ##STR2## stands for --CH.sub.2 --, X stands for O, S or NR.sup.1 wherein R.sup.1 stands for hydrogen atom or an alkyl group, Y stands for NH, O or (CH.sub.2).sub.n wherein n denotes 0 to 2, and R.sup.2 stands for an optionally substituted hydrocarbon group, or their salts.

Abstract: Homocysteine thiolactone derivatives in which the nitrogen is acylated with groups containing acidic functionalities have been synthesized. These include the succinyl, the carboxymethylglutaryl, the 3-phosphonopropionyl and the 3-sulfopropionyl derivatives. These thiolactones can be used to introduce a thiol functionality into proteins such as the outer membrane protein complex of Neisseria meninioitidis (OMPC) allowing conjugation with electrophilic ligands. This chemistry is similar to known N-acetyl-homocysteine thiolactone chemistry, but the pK.sub.a values are such that at pH 7, concomitant negative charge is introduced into the conjugate. Such negative charge neutralizes excess positive charge introduced when arginine- and lysine-rich peptides are bonded as ligands. In the case of OMPC, introduction of positive charge commonly effects irreversible precipitation of the conjugate. Conjugates prepared with the anionic thiolactones have improved solubility.